News >

BTK Inhibitors Show Continued Promise in CLL

Brandon Scalea
Published: Monday, Jul 15, 2019

Brian T. Hill, MD, PhD

Brian T. Hill, MD, PhD
Data from recent studies continue to demonstrate the potency and tolerability of BTK inhibitors as monotherapy and in combination for the treatment of patients with chronic lymphocytic leukemia (CLL) both in the frontline and relapsed/refractory settings, said Brian T. Hill, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication